The "Empagliflozin in Cardio-Renal Metabolic (CRM) Management" course offers a comprehensive exploration of the evolving role of Empagliflozin in the management of cardio-renal metabolic conditions. This course places a special emphasis on the landmark EMPA Kidney Study, a pivotal clinical trial that has far-reaching implications for a broad population of patients with chronic kidney disease (CKD) beyond its initial application in glucose control. By delving into the intricate interplay of cardio-renal-metabolic systems, participants will deepen their understanding of how cardiovascular, renal, and metabolic diseases mutually influence one another. Upon completion of this course, participants will be able to:
1. Heart Failure Updates as discussed during the ESC Conference 2023:
2. Role of Empagliflozin in CKD beyond T2DM:
3. Cardio-renal metabolic benefits of Empagliflozin:
Target Audience: Specialists, Family Physicians, General Practitioners, and Physician Assistants
Moderator: Dr. Karen Rotuk – Senior Medical Science Liaison – Boehringer Ingelheim
Time: 1600 GMT (4:00 pm local time)
AGENDA
Tuesday the 24th of October 2023 (VIRTUAL EVENT)
3:50 - 4:00 pm: Welcome
4:00 - 4:05 pm: Meeting Opening - Faculty Introductions and Scientific Agenda by Dr. Karen Rotuk
4:05 - 4:35 pm: EMPA KIDNEY: Evolving Role of Empagliflozin in CKD beyond glucose control by Dr. Yacoba Atiase.
4:35 - 4:50 pm: Case Discussion - T2D patient with low albuminuria diagnosed with CKD by Dr. Yacoba Atiase.
4:50 - 5:05 pm: ESC 2023 Heart Failure Focused Updates- Breaking barriers in HFpEF Management by Dr. Francis Agyekum
4:55 - 5:10 pm: Case Discussion - Patient newly diagnosed with HFpEF by Dr. Francis Agyekum
5:10 - 5:40 pm: Question and Answer Session Dr. Yacoba Atiase and Dr. Francis Agyekum
5:40 - 5:55 pm: 5 Key Takeaways and Closing - All
PROUDLY SPONSORED BY
This is a virtual event that will take place on Tuesday the 24th of October 2023 at 4:00 pm. The event will be streamed live on this page.
This virtual training aims to equip participants with a deep understanding of the connections between cardiovascular, renal, and metabolic conditions, and how Empagliflozin plays a pivotal role in managing these intertwined aspects of health. Participants will gain insights that can significantly impact their clinical practice and improve patient care.
Upon completion of this course, participants will be able to:
1. Understand Heart Failure Updates as discussed during the ESC Conference 2023
2. Appreciate and understand the role of Empagliflozin in CKD beyond T2DM
3. Appreciate and understand the Cardio-Renal Metabolic benefits of Empagliflozin
FWACP, MAACE, MSc, PGDip, Endo. MBChB, BSc, Cert. HAM
Senior Lecturer, Consultant Physician, Diabetologist, and Endocrinologist
Director – National Diabetes Management and Research Centre (NDMRC)
r Yakoba Atiase is the Director of the National Diabetes Management and Research Centre (NDMRC). She is also a Senior Lecturer at the University of Ghana Medical School.
View full profile / coursesMBChB, FGCP, FWACP (Int. Med – Cardiol), Cert (Interv. Cardiol)
Interventional Cardiologist and Lecturer.
Korle-Bu Teaching Hospital, and the , School Of Medicine & Dentistry, College Of Health Sciences, University Of Ghana, Legon.
Dr. Francis Agyekum is a lecturer with the University of Ghana Medical School, College of Health Sciences, Legon. He is also a Consultant Cardiologist at the Korle-Bu Teaching Hospital. Dr.
View full profile / courses